MANUEL PASCHINGER: Open Payments
NPI 1679286611 · RIVERSIDE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,521 in 115 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $332 · 2025 $2,521
Food & beverage: $2,521
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 30 | $844 |
| Teva Pharmaceuticals USA, Inc. | 19 | $332 |
| Vanda Pharmaceuticals Inc. | 14 | $274 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $266 |
| Otsuka America Pharmaceutical, Inc. | 11 | $243 |
| Lundbeck LLC | 7 | $133 |
| Janssen Pharmaceuticals, Inc | 6 | $131 |
| Alkermes, Inc. | 5 | $102 |
| Supernus Pharmaceuticals, Inc. | 4 | $98 |
| ABBVIE INC. | 2 | $49 |
Products named: INGREZZA, REXULTI, CAPLYTA, UZEDY, AUSTEDO XR, HETLIOZ, INVEGA SUSTENNA, FANAPT.
Industry payments across CA — which companies pay providers there.
